Multiple myeloma (Relapsed/Refractory) | BOSTON

FDA Decision of sNDA

Exp Date

Q1 2021

Amp Volatility Score

Catalyst Info & Data Links


  • Proteasome inhibitors (PIs):

               Velcade® (bortezomib)

                         Competitor Endeavor Trial (Velcade+Dex arm good benchmark for BOSTON results)

                         Endeavor Published Data

                         Endeavor Results Press Release

               Kyprolis® (carfilzomib)

  • Immunomodulatory agents (IMiDs):

               Revlimid® (lenalidomide)

               Pomylast® (pomalidomide)

  • Monoclonal antibodies (mAbs):


               Empliciti® (elotuzumab)

               Belantamb mafodotin (GlaxoSmithKline)

  • Nuclear export inhibitor:

               XPOVIO® (selinexor):

                         is the only drug in this class and is currently approved in heavily pretreated patients

  • Anti-BCMA therapies

               See this Evaluate article


               Bispecific antibodies


32,000 new multiple myeloma (MM) cases/yr in U.S. (2019)*

130,000 MM patients living with disease (2019)*

69,000 MM patients treated per yr (2019)**

31,000 1L

20,000 2L

12,00 3L

6,000 4L+

Earlier line - longer treatment

60,000+ patients not on active treatment or in long-term remission during 2019

Mid-single digit Increases in patient numbers annually (aging population & patients living longer      on treamtents)

*Source - Slide 23 of KPTI investor slide deck May 2020 

**Source - Slide 26 of KPTI investor slide deck May 2020


  • Nuclear export inhibitor

  • Inhibits XPO1 (see slide 5), which is believed to impact tumor cells in 3 ways

1. Increases nuclear levels and activation of tumor suppressor proteins 

2. Traps oncoprotein mRNA in the nucleus leading to reduced oncoprotein levels 

3. Retains activated glucocorticoid receptor in the nucleus

Last Updated by HC

KPTI, Selinexor, XPOVIO, multiple_myeloma, sNDA_filing_acceptance

Prior Data (click to view full image)


Trial Design / Revenue (click to view full image)


Recent Posts

See What The Community Is Saying - Click To See Full Post

KPTI's Q2 XPOVIO Net Sales...

KPTI announced their Q2 2020 XPOVIO net product sales of $18.6 Million. See AmpCard for more details. #KPTI, #XPOVIO, #SELINEXOR, #Multiple_myeloma, #STORM...

Educational video - Near-term ...

Check out my recent video in our educational forum, which discusses the unfortunate reality of small and mid-cap biopharma investing: near-term dilution. Case studies are provided for CARA and TGTX, ...

KPTI's Upcoming ASCO Presentat...

We invest in KPTI because they have an enterprise value below $2 billion, and an approved oral blood cancer drug, XPOVIO (Selinexor), with a new mechanism of action and blockbuster potential. XPOVIO i...

KPTI dilution event not a surp...

After reporting positive top-line Phase 3 results today, KTPI announced a follow-on offering. I provide more details about why this is not surprising as a comment to my Amp educational video to follow...

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon